Sociodemographic and clinical risk characteristics of patients with prostate cancer within the veterans affairs health care system: Data from capsure

被引:37
作者
Cooperberg, MR
Lubeck, DP
Penson, DF
Mehta, SS
Carroll, PR
Kane, CJ
机构
[1] Univ Calif San Francisco, Dept Urol, Program Urol Oncol, Urol Outcomes Res Grp,Mt Zion Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Vet Affairs Med Ctr, San Francisco, CA 94121 USA
[3] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA
[4] Univ Washington, Dept Urol, Seattle, WA 98195 USA
[5] TAP Pharmaceut Prod Inc, Lake Forest, IL USA
关键词
prostate; prostatic neoplasms; United States Department of Veterans Affairs; ethnicity;
D O I
10.1097/01.ju.0000081200.63275.0b
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Veterans Affairs (VA) health care system investigators perform large clinical trials in prostate cancer treatment but potential differences between VA and other patient cohorts have not been explored systematically. Materials and Methods: Cancer of the Prostate Strategic Urologic Research Endeavor is an ongoing observational database of men with prostate cancer, comprising 7,202 patients treated at 35 sites across the United States. Three sites that together contribute 241 patients are VA medical centers. Demographic and clinical characteristics were compared between all VA and nonVA patients in the database and a multivariate model was used to explore the interactions between ethnicity and VA status for predicting clinical characteristics. Results: VA patients were 4 times as likely as nonVA patients to be black. They had lower income, less education and more co-morbidity at presentation (all comparisons p <0.0001). VA patients had higher risk disease. Mean serum prostate specific antigen at diagnosis was 20.1 vs 15.3 ng/ml for nonVA patients (p = 0.003). Mean Gleason score was 6.4 for VA patients vs 6.0 for nonVA patients (p <0.0001). Differing ethnic distributions explained the differences in prostate specific antigen between VA and nonVA patients. However, VA status, socioeconomic level and ethnicity independently predicted Gleason score. VA patients were more likely to undergo watchful waiting or primary hormonal therapy and less likely to receive definitive local treatment (p <0.0001). Conclusions: Significant sociodemographic and clinical differences exist between VA and nonVA patients, which should be borne in mind when extrapolating the results of VA clinical trials to the general population. These observations require validation in larger patient cohorts.
引用
收藏
页码:905 / 908
页数:4
相关论文
共 16 条
[1]   Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy [J].
Amling, CL ;
Kane, CJ ;
Riffenburgh, RH ;
Ward, JF ;
Roberts, JL ;
Lance, RS ;
Friedrichs, PA ;
Moul, JW .
UROLOGY, 2001, 58 (05) :723-728
[2]  
BLACKARD CE, 1975, CANCER CHEMOTH REP 1, V59, P225
[3]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[4]   Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Blank, K ;
Broderick, GA ;
Tomaszewski, JE ;
Renshaw, AA ;
Kaplan, I ;
Beard, CJ ;
Wein, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974
[5]  
Feussner JR, 1998, J INVEST MED, V46, P264
[6]   Race as an outcome predictor after radical prostatectomy: Results from the shared equal access regional cancer hospital (search) database [J].
Freedland, SJ ;
Amling, CL ;
Dorey, F ;
Kane, CJ ;
Presti, JC ;
Terris, MK ;
Aronson, WJ .
UROLOGY, 2002, 60 (04) :670-674
[7]  
HRUSHESKY WJM, 1994, CANCER, V74, P2701, DOI 10.1002/1097-0142(19941101)74:9+<2701::AID-CNCR2820741820>3.0.CO
[8]  
2-H
[9]  
Kane CJ, 2002, J UROLOGY, V167, P69
[10]   Tobacco smoking and prostate cancer: Time for an appraisal [J].
Levi, F ;
La Vecchia, C .
ANNALS OF ONCOLOGY, 2001, 12 (06) :733-738